---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-23-000034"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:54:46.438081+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics Q3 net loss $8.3M; WTX-124 shows early antitumor activity

## Summary
- Cash $130.1M as of Sep 30; sufficient to fund operations through Q4 2024.
- Collaboration revenue $5.9M (vs $5.0M prior year); net loss $8.3M (vs $11.9M).
- WTX-124 Phase 1 data: well-tolerated, two unconfirmed partial responses at 12 mg, no Grade 3+ related AEs.
- WTX-330 dose escalation ongoing; WTX-124 expansion expected to open in H1 2024.
- New pipeline candidate WTX-518 (IL-18 INDUKINE) added; preclinical data in H1 2024.

## SEC filing metadata
- accession: 0001785530-23-000034
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553023000034/0001785530-23-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553023000034/howl-20231114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-23-000034
- JSON: https://secwatch.observer/filing/0001785530-23-000034.json
- Plain text: https://secwatch.observer/filing/0001785530-23-000034.txt

## Key facts
- Earnings Releases
  Werewolf Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $5.9 million.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $5.9 million
  - Result: reported results
  source text: Collaboration revenue was $5.9 million for the third quarter of 2023, compared to $5.0 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000178553023000034/0001785530-23-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.